What changed
$REGN — BUY 📊 | 6 MONTHS THESIS
🎯 Q1 2026 | Rev $3.6B | EPS $9.47 vs $8.90 🟢 | Margin 17.8%
💡 Consensus expects modest growth and a static P/E near historical median (14.7x). Variant view: estimate revisions will lift forward EPS, and the stock will re-rate toward peer averages (16–18x) as the market recognizes superior execution and pipeline progress.
📉 Reward/risk: 2.0:1
🏢 Business Quality: 8/10 - Diversified blockbuster portfolio (Eylea, Dupixent, Libtayo), strong R&D productivity, and solid free cash flow generation.
📊 Valuation: fair — 14.7x TTM P/E is at its own 50th percentile but below large-cap biotech peers (16–18x median).
🔮 Catalyst: Upward analyst estimate revisions post-earnings, plus potential pipeline data readouts at ASCO (June 2026)
💰 Entry: $614.73, stop $553, target $738
📊 Our read: BUY. Full analysis →
https://stockduty.xyz/s/REGN0617